Background: The Multicenter Study of Hydroxyurea (HU) in Sickle Cell Anemia (MSH) previously showed that daily oral HU reduces painful sickle cell (SS) crises by 50% in patients with moderate to ...

The underutilization of disease-modifying therapy by people with sickle cell disease is “persistent and alarming,” according ...

Oppenheimer analyst Matthew Biegler met with Fulcrum Therapeutics (FULC)’ management Tuesday after the company reported year-end financials.

Alex Sapir; President, Chief Executive Officer, Director; Fulcrum Therapeutics Inc. Alan Musso; Chief Financial Officer, Treasurer; Fulcrum Therapeutics Inc. Lain Fr ...

Government think tank NITI Aayog has formed a committee to create a roadmap aimed at transforming AIIMS, New Delhi, into a ...

TANZANIA: SICKLE Cell Disease (SCD) remains a significant health burden, particularly in Africa where approximately 80 per ...

The future of medicine with CRISPR and CAR-T therapy, exploring ethical, societal, and accessibility challenges in healthcare ...

NITI Aayog sets up a committee to revamp AIIMS, New Delhi, into a leading medical research and practice institution. The ...

Sickle cell disease is a severe, inherited blood disorder that primarily affects people of African, Mediterranean, Middle ...

Sickle Cell Disease Treatment Market is estimated to be valued at USD 3.20 Bn in 2025 and is expected to reach USD 8.81 Bn by 2032 exhibiting a CAGR of 15.6% Mr. Shah Coherent Market Insights Pvt. Ltd ...

BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESRE ...